Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Brigatinib Effective in ALK+ NSCLC.

Cancer discovery - 1 Jan 2017

Abstract excerpt

Results from a phase I/II trial indicate that the investigational ALK inhibitor brigatinib is active in patients with ALK-rearranged non-small cell lung cancer. Patients who had previously received crizotinib-as well as those who hadn't-responded to the drug, which was also active in patients with brain metastases.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Receptor Protein-Tyrosine Kinases
Share to Sample Size
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase I as Topic

Share to Clinical Trials, Phase II as Topic

Share to Drug Administration Schedule

Share to Organophosphorus Compounds

Share to Pyrimidines

Source

Identifiers

PMID: 27899405
DOI: 10.1158/2159-8290.CD-NB2016-151

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Brigatinib Effective in ALK+ NSCLC.PMID 27899405Read ↗

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.Semantic proximity Read ↗

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.Semantic proximity Read ↗

Design, synthesis and biological evaluation of selective inhibitors against the L858R/T790 M/C797S mutant EGFR kinase based on the scaffold of brigatinib.Semantic proximity Read ↗

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.Semantic proximity Read ↗

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: Treatment Rationale and Protocol Design of the B-DASH Study (WJOG 14720 L)Semantic proximity Read ↗

Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.Semantic proximity Read ↗

Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases.Semantic proximity Read ↗

A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.